

without reducing the frequency of minor infarction, in patients undergoing elective PCI. The question of whether the observed beneficial effects of TMZ could translate into an improved post-procedural outcome needs further investigation. Clearly, the results presented here warrant large-scale longitudinal studies to investigate the effects of pre-procedural oral TMZ treatment on late outcome in patients undergoing elective PCI.

#### Authors' affiliations

**Laurent Bonello, Pascal Sbragia, Nicolas Amabile, Olivier Com, Samuel Levy, Franck Paganelli**, Division of Cardiology, Hospital Nord, University of Marseille, School of Medicine, Marseille, France  
**Sandrine V Pierre**, Department of Pharmacology, Physiology, Metabolism and Cardiovascular Sciences, University of Toledo College of Medicine, Toledo, Ohio, USA

Competing interests: None.

#### REFERENCES

- 1 Selvanayagam JB, Porto I, Chanon K, *et al*. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury. *Circulation* 2005;**111**:1027–32.
- 2 Herrmann J, Von Birgelen C, Haude M, *et al*. Prognostic implication of cardiac troponin T increase following stent implantation. *Heart* 2002;**87**:549–53.
- 3 Lopaschuk GD. Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism. *Am J Cardiol* 1998;**82**:14K–17K.
- 4 McClellan KJ, Plosker GL. Trimetazidine: a review of its use in stable angina pectoris and others conditions. *Drugs* 1999;**58**:143–57.
- 5 Steg PG, Grollier G, Gallay P, *et al*. A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction. *Int J Cardiol* 2001;**77**:263–73.
- 6 Padadopoulos CL, Kanonidis IE, Kotridis PS, *et al*. The effect of trimetazidine on reperfusion arrhythmia in acute myocardial infarction. *Int J Cardiol* 1996;**55**:137–42.
- 7 The EMIP-FR Group (European Myocardial Infarction Project-Free Radicals). Effect on 48-h intravenous trimetazidine on short and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; a double-blind, placebo-controlled, randomized trial. *Eur Heart J* 2000;**21**:1537–46.
- 8 Di Pasquale P, Lo verso P, Bucca V, *et al*. Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: short-term and long term results. *Cardiovasc Drug Ther* 1999;**13**:423–8.
- 9 Kober G, Buck T, Sievert H, *et al*. Myocardial protection during percutaneous transluminal angioplasty: effects of trimetazidine. *Eur Heart J* 1992;**13**:1109–15.
- 10 Kovar U, Monrad ES, Sherman W, *et al*. A randomized trial of stenting with or without balloon predilatation for the treatment of coronary artery disease. *Am Heart J* 2001;**142**:e9.
- 11 Smith SC Jr, Dove JT, Jacobs AK, *et al*. Guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)—executive summary. A report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures (Committee on percutaneous transluminal coronary angioplasty). *J Am Coll Cardiol* 2001;**37**:2215–39.
- 12 Sellier P. The effects of trimetazidine on ergometric parameters in exercise-induced angina. Controlled multicenter double blind versus placebo study. *Arch Mal Cœur Vaiss* 1986;**79**:1331–6.
- 13 Scheller B, Hennen B, Pohl A, *et al*. Acute and subacute stent occlusion; risk reduction by ionic contrast media. *Eur Heart J* 2001;**22**:385–91.
- 14 Genissel P, Chodjania Y, Demolis JL, *et al*. Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers. *Eur J Drug Metab Pharmacokinet* 2004;**29**:61–8.
- 15 Stanley WC, Marzilli M. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine. *Fundam Clin Pharmacol* 2003;**17**:133–45.
- 16 Pomin M, Harpey C, Allal J, *et al*. Lack of effects of trimetazidine on systemic hemodynamics in patients with coronary artery disease: a placebo-controlled study. *Clin Trials Metaanal* 1994;**29**:49–56.
- 17 Kantor PF, Lucien A, Kozak R, *et al*. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid-oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme thiolase. *Circ Res* 2000;**86**:580–8.
- 18 Lopaschuk GD, Rick B, Panakkezhum T, *et al*. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme A thiolase. *Circ Res* 2003;**93**:e33–7.
- 19 Morin D, Elimadi A, Sapena R, *et al*. Evidence for the existence of [3H]-trimetazidine binding sites involved in the regulation of the mitochondrial permeability transition pore. *Br J Pharmacol* 1998;**123**:1385–94.
- 20 Weiss JN, Korge P, Honda HM, *et al*. Role of the mitochondrial permeability transition in myocardial disease. *Circ Res* 2003;**93**:292–301.
- 21 Argaud L, Gomez L, Gateau-Roesch O, *et al*. Trimetazidine inhibits mitochondrial permeability transition pore opening and prevents lethal ischemia-reperfusion injury. *J Mol Cell Cardiol* 2005;**39**:893–9.

#### Let us assist you in teaching the next generation

Figures from all articles on our website can be downloaded as a PowerPoint slide. This feature is ideal for teaching and saves you valuable time. Just click on the image you need and choose the "PowerPoint Slide for Teaching" option. Save the slide to your hard drive and it is ready to go. This innovative function is an important aid to any clinician, and is completely free to subscribers. (Usual copyright conditions apply.)